FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038043209> ?p ?o ?g. }

• W2038043209 endingPage "138" @default.
• W2038043209 startingPage "133" @default.
• W2038043209 abstract "It has been speculated that the use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors (statins) is associated with the risk of malignant diseases. Considering their immunosuppressive activities, malignant diseases that are associated with an immunosuppressive status seem feasible to examine the association. We therefore examined the association between statin use and development of lymphoid malignancies in a case-control study. Cases were 221 consecutive incident cases with histopathologically proven lymphoid malignancies (lymphoma and myeloma), hospitalized in the Department of Hematology of Toranomon Hospital (Tokyo, Japan) between 1995 and 2001. Two independent control groups, comprising 442 and 437 inpatients without malignancies from the Departments of Orthopedics and Otorhinolaryngology of the same hospital, were selected to test for consistency of association. Controls were matched individually with cases for age, sex and year of admission. Subject information, including statin use, was abstracted from medical records at the time of hospitalization. Strength of association was evaluated as an adjusted odds ratios (aOR) using a conditional logistic regression model. A higher frequency of statin use was found among patients with lymphoid malignancies in comparison with both orthopedic (aOR 2.11, 95% CI 1.20-3.69, P = 0.009) and otorhinolaryngology patients (aOR 2.59, 95% CI 1.45-4.65, P = 0.001), the significance being maintained when the two control groups were combined (aOR 2.24, 95% CI 1.37-3.66, P = 0.001). In conclusion, we observed an elevated risk of lymphoid malignancy with statin use among Japanese patients. Further evaluations in different populations are required to draw conclusions as to the carcinogenicity of lymphoid malignancies with statin use." @default.
• W2038043209 created "2016-06-24" @default.
• W2038043209 creator A5000117746 @default.
• W2038043209 creator A5001596834 @default.
• W2038043209 creator A5006900813 @default.
• W2038043209 creator A5009975594 @default.
• W2038043209 creator A5010482898 @default.
• W2038043209 creator A5011306623 @default.
• W2038043209 creator A5014557291 @default.
• W2038043209 creator A5044544485 @default.
• W2038043209 creator A5049518445 @default.
• W2038043209 creator A5057946980 @default.
• W2038043209 creator A5063537167 @default.
• W2038043209 creator A5065240624 @default.
• W2038043209 creator A5066277266 @default.
• W2038043209 creator A5079625930 @default.
• W2038043209 date "2006-01-25" @default.
• W2038043209 modified "2023-10-17" @default.
• W2038043209 title "Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies" @default.
• W2038043209 cites W131854666 @default.
• W2038043209 cites W1479880028 @default.
• W2038043209 cites W1525331105 @default.
• W2038043209 cites W1933695467 @default.
• W2038043209 cites W1963965901 @default.
• W2038043209 cites W1965050626 @default.
• W2038043209 cites W1968885061 @default.
• W2038043209 cites W1971246732 @default.
• W2038043209 cites W1992778715 @default.
• W2038043209 cites W2000790999 @default.
• W2038043209 cites W2001756249 @default.
• W2038043209 cites W2010945443 @default.
• W2038043209 cites W2021863348 @default.
• W2038043209 cites W2028169076 @default.
• W2038043209 cites W2035059839 @default.
• W2038043209 cites W2036132725 @default.
• W2038043209 cites W2060523549 @default.
• W2038043209 cites W2060978652 @default.
• W2038043209 cites W2079430799 @default.
• W2038043209 cites W2082768646 @default.
• W2038043209 cites W2087033359 @default.
• W2038043209 cites W2121956819 @default.
• W2038043209 cites W2129750583 @default.
• W2038043209 cites W2137647454 @default.
• W2038043209 cites W2144500318 @default.
• W2038043209 cites W2150113701 @default.
• W2038043209 cites W2153477755 @default.
• W2038043209 cites W2159413462 @default.
• W2038043209 cites W2160134407 @default.
• W2038043209 cites W2165360932 @default.
• W2038043209 cites W2247997571 @default.
• W2038043209 cites W2322095705 @default.
• W2038043209 cites W2322767982 @default.
• W2038043209 cites W2338977280 @default.
• W2038043209 cites W2522939951 @default.
• W2038043209 cites W38523360 @default.
• W2038043209 cites W4253916874 @default.
• W2038043209 cites W4376542879 @default.
• W2038043209 doi "https://doi.org/10.1111/j.1349-7006.2006.00153.x" @default.
• W2038043209 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16441424" @default.
• W2038043209 hasPublicationYear "2006" @default.
• W2038043209 type Work @default.
• W2038043209 sameAs 2038043209 @default.
• W2038043209 citedByCount "30" @default.
• W2038043209 countsByYear W20380432092012 @default.
• W2038043209 countsByYear W20380432092014 @default.
• W2038043209 countsByYear W20380432092015 @default.
• W2038043209 countsByYear W20380432092017 @default.
• W2038043209 countsByYear W20380432092018 @default.
• W2038043209 countsByYear W20380432092020 @default.
• W2038043209 countsByYear W20380432092021 @default.
• W2038043209 countsByYear W20380432092022 @default.
• W2038043209 countsByYear W20380432092023 @default.
• W2038043209 crossrefType "journal-article" @default.
• W2038043209 hasAuthorship W2038043209A5000117746 @default.
• W2038043209 hasAuthorship W2038043209A5001596834 @default.
• W2038043209 hasAuthorship W2038043209A5006900813 @default.
• W2038043209 hasAuthorship W2038043209A5009975594 @default.
• W2038043209 hasAuthorship W2038043209A5010482898 @default.
• W2038043209 hasAuthorship W2038043209A5011306623 @default.
• W2038043209 hasAuthorship W2038043209A5014557291 @default.
• W2038043209 hasAuthorship W2038043209A5044544485 @default.
• W2038043209 hasAuthorship W2038043209A5049518445 @default.
• W2038043209 hasAuthorship W2038043209A5057946980 @default.
• W2038043209 hasAuthorship W2038043209A5063537167 @default.
• W2038043209 hasAuthorship W2038043209A5065240624 @default.
• W2038043209 hasAuthorship W2038043209A5066277266 @default.
• W2038043209 hasAuthorship W2038043209A5079625930 @default.
• W2038043209 hasBestOaLocation W20380432091 @default.
• W2038043209 hasConcept C108516343 @default.
• W2038043209 hasConcept C126322002 @default.
• W2038043209 hasConcept C141071460 @default.
• W2038043209 hasConcept C146304588 @default.
• W2038043209 hasConcept C151956035 @default.
• W2038043209 hasConcept C156957248 @default.
• W2038043209 hasConcept C194409129 @default.
• W2038043209 hasConcept C195910791 @default.
• W2038043209 hasConcept C2776364478 @default.
• W2038043209 hasConcept C2776839432 @default.

• next